CC
RXRX icon

Centiva Capital’s Recursion Pharmaceuticals RXRX Stock Holding History

Centiva Capital’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-36,554
Closed -$280K – 2186
2023
Q3 		$280K Buy
+36,554
New +$365K 0.01% 1215
2023
Q2 		– Sell
-13,618
Closed -$90.8K – 1946
2023
Q1 		$90.8K Buy
+13,618
New +$108K ﹤0.01% 1353

Other funds holding RXRX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $34.8B AUM 107.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Centiva Capital's RXRX Position: Q4 2023 in Review

Centiva Capital sold out of Recursion Pharmaceuticals (RXRX) in Q4 2023, closing a stake of 36,554 shares — an estimated $280K sold.

Centiva Capital first reported a position in RXRX in Q1 2023 and held it in 2 quarters. The position peaked at $280K in Q3 2023. 199 funds tracked by Wall St. Rank hold RXRX as of Q4 2023.

  • Centiva Capital reported no remaining Recursion Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Centiva Capital sold 36,554 Recursion Pharmaceuticals shares in Q4 2023, an estimated $280K.
  • Centiva Capital first reported a position in Recursion Pharmaceuticals in Q1 2023 and held it in 2 quarters.
  • Centiva Capital's Recursion Pharmaceuticals position peaked at $280K in Q3 2023.
  • 199 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2023.

Based on Centiva Capital's 13F filing for Q4 2023, filed 14 Feb 2024.